Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06619314 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT06619314 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 56 participants.
The verdict
NCT06619314, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
Interventions
- DRUG Calderasib
- DRUG PPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2023-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06619314
The ClinicalTrials.gov registry entry for NCT06619314 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Calderasib is the first listed.
NCT06619314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06619314 about?
NCT06619314 is a clinical study titled "A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)". The purpose of this study is to evaluate the effect of food, formulation, and a PPI on the levels of calderasib in a person's body over time.
What is the current status of trial NCT06619314?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2023-09-20. Estimated completion is 2023-11-25.
What interventions are being tested in trial NCT06619314?
The interventions under investigation include: Calderasib (DRUG), PPI (DRUG).
Who is sponsoring clinical trial NCT06619314?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.